Development of IFN-γ resistance is associated with attenuation of SOCS genes induction and constitutive expression of SOCS 3 in melanoma cells

British Journal of Cancer

Volumn 97, Issue 2, 2007, Pages 231-237

  Fojtova, M ^a   Boudny, V ^b   Kovarik, A ^a   Lauerova, L ^b   Adamkova, L ^b   Souckova, K ^b   Jarkovsky, J ^c   Kovarik, J ^b  

^a INSTITUTE OF BIOPHYSICS   (Czech Republic)

^b MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^c MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Interferon resistance; Malignant melanoma; SOCS proteins; STAT phosphorylation

Indexed keywords

GAMMA INTERFERON; STAT1 PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN; STAT4 PROTEIN; STAT5 PROTEIN; STAT6 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 2; SUPPRESSOR OF CYTOKINE SIGNALING 3;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER RESISTANCE; CELL CLONE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SENSITIVITY; GENE INDUCTION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON TYPE II; MELANOMA; PHOSPHORYLATION; SKIN NEOPLASMS; STAT1 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 34447333719     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603849     Document Type: Article

References (37)

1. Alexander WS, Starr R, Fenner JE, Scott CL, Handman E, Sprigg NS, Corbin JE, Cornish AL, Darwiche R, Owczarek CM, Kay TW, Nicola NA, Hertzog PJ, Metcalf D, Hilton DJ (1999) SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell 98: 597-608
2. Boudny V, Kocak I, Lauerova L, Kovarik J (2003) Interferon inducibility of STAT 1 activation and its prognostic significance in melanoma patients. Folia Biol (Praha) 49: 142-146
3. Brierley MM, Fish EN (2005) Stats: multifaceted regulators of transcription. J Interferon Cytokine Res 25: 733-744
4. Calo V, Migliavacca M, Bazan V, Macaluso M, Buscemi M, Gebbia N, Russo A (2003) STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol 197: 157-168
5. Chawla-Sarkar M, Leaman DW, Jacobs BS, Borden EC (2002) IFN-beta pretreatment sensitizes human melanoma cells to TRAIL/Apo2 ligand-induced apoptosis. J Immunol 169: 847-855
6. Chow M, Rubin H (2000) Clonal selection versus genetic instability as the driving force in neoplastic transformation. Cancer Res 60: 6510-6518
7. Durbin JE, Hackenmiller R, Simon MC, Levy DE (1996) Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 84: 443-450
8. Evans MK, Yu CR, Lohani A, Mahdi RM, Liu X, Trzeciak AR, Egwuagu CE (2007) Expression of SOCS1 and SOCS3 genes is differentially regulated in breast cancer cells in response to proinflammatory cytokine and growth factor signals. Oncogene 26: 1941-1948
9. Fojtova M, Van Houdt H, Depicker A, Kovarik A (2003) Epigenetic switch from posttranscriptional to transcriptional silencing is correlated with promoter hypermethylation. Plant Physiol 133: 1240-1250
10. Fujimoto M, Naka T (2003) Regulation of cytokine signaling by SOCS family molecules. Trends Immunol 24: 659-666
11. He B, You L, Uematsu K, Zang K, Xu Z, Lee AY, Costello JF, McCormick F, Jablons DM (2003) SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci USA 100: 14133-14138
12. Hebenstreit D, Luft P, Schmiedlechner A, Duschl A, Horejs-Hoeck J (2005) SOCS-1 and SOCS-3 inhibit IL-4 and IL-13 induced activation of Eotaxin-3/CCL26 gene expression in HEK293 cells. Mol Immunol 42: 295-303
13. Hilton DJ (1999) Negative regulators of cytokine signal transduction. Cell Mol Life Sci 55: 1568-1577
14. Jackson DP, Watling D, Rogers NC, Banks RE, Kerr IM, Selby PJ, Patel PM (2003) The JAK/STAT pathway is not sufficient to sustain the antiproliferative response in an interferon-resistant human melanoma cell line. Melanoma Res 13: 219-229
15. Komazaki T, Nagai H, Emi M, Terada Y, Yabe A, Jin E, Kawanami O, Konishi N, Moriyama Y, Naka T, Kishimoto T (2004) Hypermethylation-associated inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human pancreatic cancers. Jpn J Clin Oncol 34: 191-194
16. Kortylewski M, Komyod W, Kauffmann ME, Bosserhoff A, Heinrich PC, Behrmann I (2004) Interferon-gamma-mediated growth regulation of melanoma cells: involvement of STAT1-dependent and STAT1-independent signals. J Invest Dermatol 122: 414-422
17. Kovarik A, Fojtova M, Boudny V, Adamkova L, Lauerova L, Kovarik J (2005) Interferon-gamma, but not interferon-alpha, induces SOCS 3 expression in human melanoma cell lines. Melanoma Res 15: 481-488
18. Kovarik A, Peat N, Wilson D, Gendler SJ, Taylor-Papadimitriou J (1993) Analysis of the tissue-specific promoter of the MUC1 gene. J Biol Chem 268: 9917-9926
19. Kovarik J, Boudny V, Kocak I, Lauerova L, Fait V, Vagundova M (2003) Malignant melanoma associates with deficient IFN-induced STAT 1 phosphorylation. Int J Mol Med 12: 335-340
20. Kovarik P, Mangold M, Ramsauer K, Heidari H, Steinborn R, Zotter A, Levy DE, Muller M, Decker T (2001) Specificity of signaling by STAT1 depends on SH2 and C-terminal domains that regulate Ser727 phosphorylation, differentially affecting specific target gene expression. EMBO J 20: 91-100
21. Lee KY, Anderson E, Madani K, Rosen GD (1999) Loss of STAT1 expression confers resistance to IFN-gamma-induced apoptosis in ME180 cells. FEBS Lett 459: 323-326
22. Lens MB, Dawes M (2002) Interferon alpha therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol 20: 1818-1825
23. Lesinski GB, Valentino D, Hade EM, Jones S, Magro C, Chaudhury AR, Walker MJ, Carson III WE (2005) Expression of STAT1 and STAT2 in malignant melanoma does not correlate with response to interferon-alpha adjuvant therapy. Cancer Immunol Immunother 54: 815-825
24. Li Z, Metze D, Nashan D, Muller-Tidow C, Serve HL, Poremba C, Luger TA, Bohm M (2004) Expression of SOCS-1, suppressor of cytokine signalling-1, in human melanoma. J Invest Dermatol 123: 737-745
25. Lu C, Rak JW, Kobyashi H, Kerbel RS (1993) Increased resistance to oncostatin M-induced growth inhibition of human melanoma cell lines derived from advanced-staged lesions. Cancer Res 53: 2708-2711
26. Masuhara M, Sakamoto H, Matsumoto A, Suzuki R, Yasukawa H, Mitsui K, Wakioka T, Tanimura S, Sasaki A, Misawa H, Yokouchi M, Ohtsubo M, Yoshimura A (1997) Cloning and characterization of novel CIS family genes. Biochem Biophys Res Commun 239: 439-446
27. Pansky A, Hildebrand P, Fasler-Kan E, Baselgia L, Ketterer S, Beglinger C, Heim MH (2000) Defective Jak-STAT signal transduction pathway in melanoma cells resistant to growth inhibition by interferon-alpha. Int J Cancer 85: 720-725
28. Ramana CV, Kumar A, Enelow R (2005) Stat1-independent induction of SOCS-3 by interferon-gamma is mediated by sustained activation of Stat3 in mouse embryonic fibroblasts. Biochem Biophys Res Commun 327: 727-733
29. Ransohoff RM (1998) Cellular responses to interferons and other cytokines: the JAK-STAT paradigm. N Engl J Med 338: 616-618
30. Sakai I, Takeuchi K, Yamauchi H, Narumi H, Fujita S (2002) Constitutive expression of SOCS3 confers resistance to IFN-alpha in chronic myelogenous leukemia cells. Blood 100: 2926-2931
31. Shuai K, Ziemiecki A, Wilks AF, Harpur AG, Sadowski HB, Gilman MZ, Darnell JE (1993) Polypeptide signaling to the nucleus through tyrosine phosphorylation of Jak and Stat proteins. Nature 366: 580-583
32. Sutherland KD, Lindeman GJ, Choong DYH, Wittlin S, Brentzell L, Phillips W, Campbell IG, Visvader JE (2004) Differential hypermethylation of SOCS genes in ovarian and breast carcinomas. Oncogene 23: 7726-7733
33. Timofeeva OA, Plisov S, Evseev AA, Peng S, Jose-Kampfner M, Lovvorn HN, Dome JS, Perantoni AO (2006) Serine-phosphorylated STAT1 is a prosurvival factor in Wilms' tumor pathogenesis. Oncogene 25: 7555-7564
34. Weber A, Hengge UR, Bardenheuer W, Tischoff I, Sommerer F, Markwarth A, Dietz A, Wittekind C, Tannapfel A (2005) SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition. Oncogene 24: 6699-6708
35. Wellbrock C, Weisser C, Hassel JC, Fischer P, Becker J, Vetter CS, Behrmann I, Kortylewski M, Heinrich PC, Schartl M (2005) STAT5 contributes to interferon resistance of melanoma cells. Curr Biol 15: 1629-1639
36. Wong LH, Krauer KG, Hatzinisiriou I, Estcourt MJ, Hersey P, Tam ND, Edmondson S, Devenish RJ, Ralph SJ (1997) Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. J Biol Chem 272: 28779-28885
37. Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning JE, Harris CC, Herman JG (2001) SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 28: 29-35